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Taking together these two independent, unfunded studies using hard clinical endpoints, we agree with the conclusion of Cusick and Beverland 2 that, in patients without additional risk factors, arthroplasty surgery is not a high-risk procedure for fatal pulmonary embolism. Author's reply:
Sir, We thank Messrs Clayton et al for their interest in our paper. However, we have to correct a misinterpretation of our study: surrogate endpoints were not used in this analysis; only pre-specified symptomatic endpoints were included. The large patient numbers in our database allowed an analysis of the composite endpoint of symptomatic venous thromboembolism (VTE) and all-cause mortality.
The clinical important of symptomatic VTE complications should not be underestimated in terms of patient burden, economic cost and quality of life. Focusing on fatal pulmonary embolism only, as noted in the letter by Clayton et al, is scientifically and medically inaccurate.
From a clinical perspective, symptomatic VTE can lead to prolonged hospitalisation, increased NHS costs and long-term sequelae such as recurrent VTE, post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension, which can affect morbidity, mortality and quality of life.
1,2 Moreover, fatal pulmonary embolism is now a rare event in this population and, as Clayton et al discuss in their paper, clinical studies enrolling very large patient numbers would be required to demonstrate a significant reduction in fatal pulmonary embolism. 3 The incidence of fatal pulmonary embolism is reported in our paper (0% with rivaroxaban, < 0.01% with enoxaparin regimens). However, as clinicians are well aware, the reported incidence of fatal pulmonary embolism is not always accurate given the very low autopsy rate.
Despite the differences noted in age profiles between our study and that of Cusick and Beverland, 4 the patient demographics in the RECORD 1-3 analysis were representative of those seen in clinical practice, as supported by demographic data from the GLORY registry.
